Edgewise Therapeutics, Inc. Insider Trading

EWTX

Last 12 months

Insiders bought 199K and sold $19.5M on the open market.

79% of the selling was scheduled in advance under 10b5-1 plans. Chief Scientific Officer Alan J Russell sold $2.11M on Nov 12, 2025, 81% of their stake, outside a plan.

Net open-market

−$19.3M

1 buy · 12 sales

Under a 10b5-1 plan

79%

of the value sold

Insiders who bought / sold

1 / 6

executives and directors

Last open-market buy

Nov 2025

Nov 11, 2025

Get an email when EWTX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 12 – 13	Joanne M. Donovan CMO	SoldNo plan 5 parts	9,441	$43.71 average	413K	52%	Form 4
Aug 12	Alan J Russell Chief Scientific Officer	SoldNo plan 3 parts	5,901	$43.73 average	258K	16%	Form 4
Aug 12	Behrad Derakhshan Chief Business Officer	SoldNo plan 4 parts	5,100	$43.81 average	223K	14%	Form 4
Aug 12	John R Moore General Counsel	SoldNo plan 4 parts	5,016	$43.83 average	220K	22%	Form 4
Aug 12	Kevin Koch President and CEO	SoldNo plan 3 parts	17,971	$43.68 average	785K	26%	Form 4
Jul 1	Alan J Russell Chief Scientific Officer	Sold10b5-1 plan 2 parts	200,000	$39.41 average	$7.88M	89%	Form 4
May 4 – 5	Joanne M. Donovan CMO	Sold10b5-1 plan 2 parts	55,230	$37.88 average	$2.09M	93%	Form 4
Apr 1	Joanne M. Donovan CMO	Sold10b5-1 plan	28,662	$32.31	926K	75%	Form 4
Mar 31	Joanne M. Donovan CMO	Sold10b5-1 plan	21,338	$32.12	685K	69%	Form 4
Mar 27	Joanne M. Donovan CMO	Sold10b5-1 plan 2 parts	16,358	$30.98 average	507K	63%	Form 4
Jan 21	Badreddin Edris Director	Sold10b5-1 plan 5 parts	115,471	$29.44 average	$3.4M	85%	Form 4
Nov 12, 2025	Alan J Russell Chief Scientific Officer	SoldNo plan	100,000	$21.12	$2.11M	81%	Form 4
Nov 11, 2025	Jonathan C Fox Director	Bought	10,700	$18.64	199K	82%	Form 4
Aug 26, 2025	Alan J Russell Chief Scientific Officer	SoldNo plan	100,000	$14.60	$1.46M	81%	Form 4
Aug 12, 2025	John R Moore General Counsel	SoldNo plan	2,098	$13.39	28K	17%	Form 4
Aug 12, 2025	Behrad Derakhshan Chief Business Officer	SoldNo plan	2,491	$13.39	33K	9.5%	Form 4
Aug 12, 2025	R Michael Carruthers Chief Financial Officer	SoldNo plan	1,428	$13.39	19K	1.6%	Form 4
Aug 12, 2025	Alan J Russell Chief Scientific Officer	SoldNo plan	1,907	$13.39	26K	7.5%	Form 4
Aug 12, 2025	Kevin Koch President and CEO	SoldNo plan	7,972	$13.39	107K	2.1%	Form 4
Aug 12, 2025	Joanne M. Donovan CMO	SoldNo plan	2,862	$13.39	38K	10%	Form 4
May 2, 2025	Alan J Russell Chief Scientific Officer	SoldNo plan	1,551	$16.45	26K	7.7%	Form 4
May 2, 2025	John R Moore General Counsel	SoldNo plan	1,930	$16.45	32K	23%	Form 4
May 2, 2025	Kevin Koch President and CEO	SoldNo plan	4,276	$16.45	70K	1.1%	Form 4
May 2, 2025	Joanne M. Donovan CMO	SoldNo plan	5,187	$16.45	85K	19%	Form 4
May 2, 2025	Behrad Derakhshan Chief Business Officer	SoldNo plan	1,691	$16.45	28K	7.7%	Form 4
May 2, 2025	R Michael Carruthers Chief Financial Officer	SoldNo plan	1,314	$16.45	22K	1.6%	Form 4
Apr 3, 2025	Peter A. Thompson Director	Bought 2 parts	496,771	$20.13 average	$10M	New	Form 4
Apr 3, 2025	Orbimed Genesis GP LLC Large holder	Bought 2 parts	496,771	$20.13 average	$10M	New	Form 4
Mar 7, 2025	Alan J Russell Chief Scientific Officer	Sold10b5-1 plan	200	$30.02	6K	1.3%	Form 4
Mar 7, 2025	Kevin Koch President and CEO	Sold10b5-1 plan	100	$30.00	3K	<0.1%	Form 4
Feb 5, 2025 – Feb 6, 2025	Alan J Russell Chief Scientific Officer	Sold10b5-1 plan 2 parts	9,215	$30.03 average	277K	38%	Form 4
Feb 5, 2025 – Feb 6, 2025	Kevin Koch President and CEO	Sold10b5-1 plan 2 parts	9,536	$30.13 average	287K	2.6%	Form 4
Feb 5, 2025	Behrad Derakhshan Chief Business Officer	Sold10b5-1 plan	10,000	$30.03	300K	37%	Form 4
Jan 28, 2025	Joanne M. Donovan CMO	Sold10b5-1 plan	25,000	$27.63	691K	60%	Form 4
Dec 30, 2024	Alan J Russell Chief Scientific Officer	Sold10b5-1 plan	100,000	$27.37	$2.74M	87%	Form 4
Dec 24, 2024	Marc Semigran Chief Development Officer	Sold10b5-1 plan 2 parts	29,709	$29.68 average	882K	82%	Form 4

Aug 12 – 13No plan
Joanne M. Donovan
CMO · sold 9,441 at avg $43.71
413K
52% of stake
Aug 12No plan
Alan J Russell
Chief Scientific Officer · sold 5,901 at avg $43.73
258K
16% of stake
Aug 12No plan
Behrad Derakhshan
Chief Business Officer · sold 5,100 at avg $43.81
223K
14% of stake
Aug 12No plan
John R Moore
General Counsel · sold 5,016 at avg $43.83
220K
22% of stake
Aug 12No plan
Kevin Koch
President and CEO · sold 17,971 at avg $43.68
785K
26% of stake
Jul 110b5-1 plan
Alan J Russell
Chief Scientific Officer · sold 200,000 at avg $39.41
$7.88M
89% of stake
May 4 – 510b5-1 plan
Joanne M. Donovan
CMO · sold 55,230 at avg $37.88
$2.09M
93% of stake
Apr 110b5-1 plan
Joanne M. Donovan
CMO · sold 28,662 at $32.31
926K
75% of stake
Mar 3110b5-1 plan
Joanne M. Donovan
CMO · sold 21,338 at $32.12
685K
69% of stake
Mar 2710b5-1 plan
Joanne M. Donovan
CMO · sold 16,358 at avg $30.98
507K
63% of stake
Jan 2110b5-1 plan
Badreddin Edris
Director · sold 115,471 at avg $29.44
$3.4M
85% of stake
Nov 12, 2025No plan
Alan J Russell
Chief Scientific Officer · sold 100,000 at $21.12
$2.11M
81% of stake
Nov 11, 2025
Jonathan C Fox
Director · bought 10,700 at $18.64
199K
82% of stake
Aug 26, 2025No plan
Alan J Russell
Chief Scientific Officer · sold 100,000 at $14.60
$1.46M
81% of stake
Aug 12, 2025No plan
John R Moore
General Counsel · sold 2,098 at $13.39
28K
17% of stake
Aug 12, 2025No plan
Behrad Derakhshan
Chief Business Officer · sold 2,491 at $13.39
33K
9.5% of stake
Aug 12, 2025No plan
R Michael Carruthers
Chief Financial Officer · sold 1,428 at $13.39
19K
1.6% of stake
Aug 12, 2025No plan
Alan J Russell
Chief Scientific Officer · sold 1,907 at $13.39
26K
7.5% of stake
Aug 12, 2025No plan
Kevin Koch
President and CEO · sold 7,972 at $13.39
107K
2.1% of stake
Aug 12, 2025No plan
Joanne M. Donovan
CMO · sold 2,862 at $13.39
38K
10% of stake
May 2, 2025No plan
Alan J Russell
Chief Scientific Officer · sold 1,551 at $16.45
26K
7.7% of stake
May 2, 2025No plan
John R Moore
General Counsel · sold 1,930 at $16.45
32K
23% of stake
May 2, 2025No plan
Kevin Koch
President and CEO · sold 4,276 at $16.45
70K
1.1% of stake
May 2, 2025No plan
Joanne M. Donovan
CMO · sold 5,187 at $16.45
85K
19% of stake
May 2, 2025No plan
Behrad Derakhshan
Chief Business Officer · sold 1,691 at $16.45
28K
7.7% of stake
May 2, 2025No plan
R Michael Carruthers
Chief Financial Officer · sold 1,314 at $16.45
22K
1.6% of stake
Apr 3, 2025
Peter A. Thompson
Director · bought 496,771 at avg $20.13
$10M
New position
Apr 3, 2025
Orbimed Genesis GP LLC
Large holder · bought 496,771 at avg $20.13
$10M
New position
Mar 7, 202510b5-1 plan
Alan J Russell
Chief Scientific Officer · sold 200 at $30.02
6K
1.3% of stake
Mar 7, 202510b5-1 plan
Kevin Koch
President and CEO · sold 100 at $30.00
3K
<0.1% of stake
Feb 5, 2025 – Feb 6, 202510b5-1 plan
Alan J Russell
Chief Scientific Officer · sold 9,215 at avg $30.03
277K
38% of stake
Feb 5, 2025 – Feb 6, 202510b5-1 plan
Kevin Koch
President and CEO · sold 9,536 at avg $30.13
287K
2.6% of stake
Feb 5, 202510b5-1 plan
Behrad Derakhshan
Chief Business Officer · sold 10,000 at $30.03
300K
37% of stake
Jan 28, 202510b5-1 plan
Joanne M. Donovan
CMO · sold 25,000 at $27.63
691K
60% of stake
Dec 30, 202410b5-1 plan
Alan J Russell
Chief Scientific Officer · sold 100,000 at $27.37
$2.74M
87% of stake
Dec 24, 202410b5-1 plan
Marc Semigran
Chief Development Officer · sold 29,709 at avg $29.68
882K
82% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch EWTX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with EWTX

CompareIntrinsic value

ORGOOrganogenesis Holdings Inc.

$0.87+4.19%50

AUPHAurinia Pharmaceuticals Inc.

$17.11+3.32%58

PRAXPraxis Precision Medicines Inc.

$284.79+1.53%10

VNDAVanda Pharmaceuticals Inc.

$3.88+3.47%10

CYRXCryoport Inc.

$16.70+1.52%13

BRNSBarinthus Biotherapeutics plc.

No recent price10

ARDXArdelyx Inc.

$3.27+7.92%40

LLYEli Lilly and Company

$1,418.07+0.62%73

Held by ETFs

EWTX is in 44 US ETFs. The largest of them, with EWTX's weight in each:

Spot a number that looks wrong? Check it in EWTX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing EWTX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.